An update on colorectal cancer biomarkers: exploring the roles of c-Jun and IL-8.

IF 2.1 4区医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL

Biomarkers in medicine Pub Date : 2025-12-01 Epub Date: 2025-12-06 DOI:10.1080/17520363.2025.2597174

Nur Rahadiani, Marini Stephanie, Kathryn Effendi, Amelia Fossetta Manatar, Ening Krisnuhoni

{"title":"An update on colorectal cancer biomarkers: exploring the roles of c-Jun and IL-8.","authors":"Nur Rahadiani, Marini Stephanie, Kathryn Effendi, Amelia Fossetta Manatar, Ening Krisnuhoni","doi":"10.1080/17520363.2025.2597174","DOIUrl":null,"url":null,"abstract":"Objective: Colorectal cancer (CRC) is a major contributor to global cancer mortality. Reliable biomarkers like c-Jun and Interleukin-8 (IL-8) may improve prognosis and therapy. Considering the possible ethnic differences in CRC biomarkers, this study is the first to examine a distinct Southeast Asian cohort (Indonesia).Methods: A retrospective study analyzed 98 CRC patients using immunohistochemistry to evaluate c-Jun and IL-8 expression. Paraffin-embedded tissues were assessed for correlations with clinicopathological features. Statistical analyses were performed with p < 0.05 considered significant.Results: c-Jun expression was significantly higher in mucinous or serrated histology (median 1.80, range 0.90-2.30) compared to adenocarcinoma, NOS (median 1.60, range 0.70-2.50) (p = 0.04). Meanwhile, IL-8 expression showed no significant differences across all clinicopathological factors. Neither biomarkers showed significant association with most clinicopathological factors, including age, sex, tumor size, location, stage, grade, invasion, or metastasis.Conclusions: c-Jun and IL-8 expression showed limited prognostic relevance for most clinicopathological features of CRC. However, elevated c-Jun expression may indicate its particular involvement in distinct CRC subtype pathogenesis.","PeriodicalId":9182,"journal":{"name":"Biomarkers in medicine","volume":" ","pages":"1227-1238"},"PeriodicalIF":2.1000,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12758331/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomarkers in medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17520363.2025.2597174","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/12/6 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: Colorectal cancer (CRC) is a major contributor to global cancer mortality. Reliable biomarkers like c-Jun and Interleukin-8 (IL-8) may improve prognosis and therapy. Considering the possible ethnic differences in CRC biomarkers, this study is the first to examine a distinct Southeast Asian cohort (Indonesia).

Methods: A retrospective study analyzed 98 CRC patients using immunohistochemistry to evaluate c-Jun and IL-8 expression. Paraffin-embedded tissues were assessed for correlations with clinicopathological features. Statistical analyses were performed with p < 0.05 considered significant.

Results: c-Jun expression was significantly higher in mucinous or serrated histology (median 1.80, range 0.90-2.30) compared to adenocarcinoma, NOS (median 1.60, range 0.70-2.50) (p = 0.04). Meanwhile, IL-8 expression showed no significant differences across all clinicopathological factors. Neither biomarkers showed significant association with most clinicopathological factors, including age, sex, tumor size, location, stage, grade, invasion, or metastasis.

Conclusions: c-Jun and IL-8 expression showed limited prognostic relevance for most clinicopathological features of CRC. However, elevated c-Jun expression may indicate its particular involvement in distinct CRC subtype pathogenesis.

查看原文本刊更多论文

结直肠癌生物标志物的最新进展：探讨c-Jun和IL-8的作用

目的：结直肠癌（CRC）是全球癌症死亡的主要原因。可靠的生物标志物如c-Jun和白细胞介素-8 （IL-8）可能改善预后和治疗。考虑到结直肠癌生物标志物可能存在的种族差异，本研究首次研究了一个独特的东南亚队列（印度尼西亚）。方法：回顾性分析98例结直肠癌患者，采用免疫组化方法检测c-Jun和IL-8的表达。评估石蜡包埋组织与临床病理特征的相关性。结果：c-Jun在粘液或锯齿状组织中的表达（中位数1.80，范围0.90-2.30）明显高于腺癌和NOS（中位数1.60，范围0.70-2.50）（p = 0.04）。同时，IL-8的表达在各临床病理因素间无显著差异。两种生物标志物均未显示出与大多数临床病理因素的显著相关性，包括年龄、性别、肿瘤大小、位置、分期、分级、侵袭或转移。结论：c-Jun和IL-8的表达与CRC的大多数临床病理特征的预后相关性有限。然而，升高的c-Jun表达可能表明其在不同CRC亚型发病机制中的特殊参与。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Biomarkers in medicine 医学-医学：研究与实验

CiteScore

3.80

自引率

4.50%

发文量

审稿时长

6-12 weeks

期刊介绍： Biomarkers are physical, functional or biochemical indicators of physiological or disease processes. These key indicators can provide vital information in determining disease prognosis, in predicting of response to therapies, adverse events and drug interactions, and in establishing baseline risk. The explosion of interest in biomarker research is driving the development of new predictive, diagnostic and prognostic products in modern medical practice, and biomarkers are also playing an increasingly important role in the discovery and development of new drugs. For the full utility of biomarkers to be realized, we require greater understanding of disease mechanisms, and the interplay between disease mechanisms, therapeutic interventions and the proposed biomarkers. However, in attempting to evaluate the pros and cons of biomarkers systematically, we are moving into new, challenging territory. Biomarkers in Medicine (ISSN 1752-0363) is a peer-reviewed, rapid publication journal delivering commentary and analysis on the advances in our understanding of biomarkers and their potential and actual applications in medicine. The journal facilitates translation of our research knowledge into the clinic to increase the effectiveness of medical practice. As the scientific rationale and regulatory acceptance for biomarkers in medicine and in drug development become more fully established, Biomarkers in Medicine provides the platform for all players in this increasingly vital area to communicate and debate all issues relating to the potential utility and applications. Each issue includes a diversity of content to provide rounded coverage for the research professional. Articles include Guest Editorials, Interviews, Reviews, Research Articles, Perspectives, Priority Paper Evaluations, Special Reports, Case Reports, Conference Reports and Company Profiles. Review coverage is divided into themed sections according to area of therapeutic utility with some issues including themed sections on an area of topical interest. Biomarkers in Medicine provides a platform for commentary and debate for all professionals with an interest in the identification of biomarkers, elucidation of their role and formalization and approval of their application in modern medicine. The audience for Biomarkers in Medicine includes academic and industrial researchers, clinicians, pathologists, clinical chemists and regulatory professionals.